Mismatch-repair-deficient endometrial cancer

What changed: Mismatch-repair-deficient endometrial cancer

Cancer page →

Every dated change on the records linked to Mismatch-repair-deficient endometrial cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result4Milestone6This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordMismatch-repair-deficient endometrial cancer
Facts on this page last checked
When this page itself was last checked or edited.

2024 · 1

2024MilestoneStudy of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
KEYNOTE-B21: adjuvant pembrolizumab misses its primary endpoint overall; dMMR subgroup appears to benefit
A milestone in how this cancer is treated.

2023 · 5

2021 · 1

2021MilestoneDostarlimab
Dostarlimab approved for recurrent dMMR endometrial cancer after GARNET
A milestone in how this cancer is treated.

2018 · 1

2018Trial resultPORTEC-3
PORTEC-3 reported
5-year OS 81.

2017 · 1

2017MilestonePembrolizumab
Pembrolizumab: first tumour-agnostic approval, for mismatch-repair-deficient tumours
A milestone in how this cancer is treated.

2013 · 1

2013MilestoneEndometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)
TCGA describes the hypermutated MSI class of endometrial cancer
A milestone in how this cancer is treated.